Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

smallpox vaccine live, New York City Board of Health vaccinia strain · Acam2000, ACAM2000

Vaccine (Live attenuated vaccine) · Immune activation, directed at orthopoxvirus vaccinia virus · developed by Emergent Product Development Gaithersburg

Approved FDA, Aug 2007

EBS Developer

5 Registered trials

What is smallpox vaccine live, New York City Board of Health vaccinia strain?

ACAM2000 is a live attenuated vaccinia virus vaccine administered percutaneously for smallpox prevention. It is a live viral vaccine that stimulates immune responses against orthopoxviruses.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Acam2000, ACAM2000
Drug type: Vaccine (Live attenuated vaccine)
Targets: orthopoxvirus vaccinia virus (antigen)
Mechanism: Immune activation, directed at orthopoxvirus vaccinia virus
Pathways: immune_activation
Therapy area: Infectious disease
Developer: Emergent Product Development Gaithersburg, Inc. (EBS)
FDA status: Approved as Acam2000 (August 31, 2007), BLA125158
UNII: 4SV59689SK

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02443623	Phase 4	Smallpox Vaccine Adverse Reaction	Completed	EBS
NCT01158157	Phase 3	Smallpox Vaccine Adverse Reaction	Completed	EBS
NCT00053482	Phase 2	Smallpox	Completed	EBS
NCT00053495	Phase 2	Smallpox	Completed	EBS
NCT00927719	N/A	Smallpox	Completed	EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

SmallpoxSmallpox Vaccine Adverse Reaction

More from Emergent Product Development Gaithersburg

AIGIV FDA approved Bacillus anthracis strain V770-NP1-R antigens FDA approved Brincidofovir FDA approved Vaccinia Immune Globulin FDA approved Ad4-EnvC150 Phase 1 Ad4-H5-Vtn Phase 1 Ad4-mgag Phase 1 Ad4-PA-1 Phase 1 Ad4-PA-GPI-1 Phase 1 AIDSVAX B/E Phase 1 AV7909 Phase 3 Botulinum Antitoxin Heptavalent Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind smallpox vaccine live, New York City Board of Health vaccinia strain

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z